List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/11800267/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Defining <scp>highâ€risk</scp> elective contralateral neck radiation volumes for oropharynx cancer. Head and Neck, 2022, 44, 317-324.	2.0	1
2	Nodal Metastasis Count and Oncologic Outcomes in Head and Neck Cancer: A Secondary Analysis of NRG/RTOG 9501, NRG/RTOG 0234, and EORTC 22931. International Journal of Radiation Oncology Biology Physics, 2022, 113, 787-795.	0.8	6
3	Prospective Study of PET/MRI Tumor Response During Chemoradiotherapy for Patients With Low-risk and Intermediate-risk p16-positive Oropharynx Cancer. American Journal of Clinical Oncology: Cancer Clinical Trials, 2022, 45, 202-207.	1.3	4
4	Evolutionary Action Score of TP53 Analysis in Pathologically High-Risk Human Papillomavirus-Negative Head and Neck Cancer From a Phase 2 Clinical Trial: NRG Oncology Radiation Therapy Oncology Group 0234. Advances in Radiation Oncology, 2022, 7, 100989.	1.2	1
5	Validation of Monte Carlo ¹³¹ I radiopharmaceutical dosimetry workflow using a 3Dâ€printed anthropomorphic head and neck phantom. Medical Physics, 2022, 49, 5491-5503.	3.0	3
6	Longitudinal Molecular Profiling of Circulating Tumor Cells in Metastatic Renal Cell Carcinoma. Journal of Clinical Oncology, 2022, 40, 3633-3641.	1.6	12
7	Stress Keratin 17 Expression in Head and Neck Cancer Contributes to Immune Evasion and Resistance to Immune-Checkpoint Blockade. Clinical Cancer Research, 2022, 28, 2953-2968.	7.0	12
8	Stress keratin 17 as a novel biomarker of response in immune checkpoint blockade–treated head and neck squamous cell carcinoma Journal of Clinical Oncology, 2022, 40, 3117-3117.	1.6	0
9	Targeting HER3-dependent activation of nuclear AKT improves radiotherapy of non-small cell lung cancer. Radiotherapy and Oncology, 2022, , .	0.6	2
10	Treating Advanced Head and Neck Cancer When Cisplatin Is Not an Option. Journal of Clinical Oncology, 2021, 39, 7-12.	1.6	6
11	Refining Guidelines Regarding Unilateral Treatment in Patients With Well-lateralized Squamous Cell Carcinoma of the Palatine Tonsil and Multiple Positive Nodes or Extranodal Extension. Practical Radiation Oncology, 2021, 11, e247-e251.	2.1	2
12	Declining Medical Student Interest in Radiation Oncology: Wake-Up Call With a Silver Lining?. International Journal of Radiation Oncology Biology Physics, 2021, 110, 274-277.	0.8	5
13	Why an Increasing Number of Unmatched Residency Positions in Radiation Oncology? A Survey of Fourth-Year Medical Students. Advances in Radiation Oncology, 2021, 6, 100743.	1.2	2
14	Combining Stereotactic Body Radiotherapy and Microwave Ablation Appears Safe and Feasible for Renal Cell Carcinoma in an Early Series. Clinical Genitourinary Cancer, 2021, 19, e313-e318.	1.9	4
15	Primary head and neck tumour-derived fibroblasts promote lymphangiogenesis in a lymphatic organotypic co-culture model. EBioMedicine, 2021, 73, 103634.	6.1	19
16	The Model of an ASTRO Servant Leader. International Journal of Radiation Oncology Biology Physics, 2021, 111, 1120-1121.	0.8	0
17	Human Tumor‣ymphatic Microfluidic Model Reveals Differential Conditioning of Lymphatic Vessels by Breast Cancer Cells. Advanced Healthcare Materials, 2020, 9, e1900925.	7.6	45
18	Clinical Implications of Scleroderma in the Decision for Radiotherapy-Based Larynx Preservation. JAMA Otolaryngology - Head and Neck Surgery, 2020, 146, 308.	2.2	0

#	Article	IF	CITATIONS
19	Blocking Y-Box Binding Protein-1 through Simultaneous Targeting of PI3K and MAPK in Triple Negative Breast Cancers. Cancers, 2020, 12, 2795.	3.7	14
20	Practice recommendations for risk-adapted head and neck cancer radiotherapy during the COVID-19 pandemic: An ASTRO-ESTRO consensus statement. Radiotherapy and Oncology, 2020, 151, 314-321.	0.6	24
21	Life Beyond COVID: Pay Attention to Viruses. International Journal of Radiation Oncology Biology Physics, 2020, 108, 348-350.	0.8	0
22	Peer review program to enhance treatment planning quality assurance for community radiation oncologists. Journal of Radiation Oncology, 2020, 9, 131-138.	0.7	1
23	Fibroblast Growth Factor Receptors as Targets for Radiosensitization in Head and Neck Squamous Cell Carcinomas. International Journal of Radiation Oncology Biology Physics, 2020, 107, 793-803.	0.8	10
24	Emphasize Treatment of Known Disease Rather Than Past Footprints. International Journal of Radiation Oncology Biology Physics, 2020, 106, 904.	0.8	0
25	Clinical outcomes for larynx patients with cancer treated with refinement of highâ€dose radiation treatment volumes. Head and Neck, 2020, 42, 1874-1881.	2.0	4
26	The Promise of Combining Radiation Therapy With Immunotherapy. International Journal of Radiation Oncology Biology Physics, 2020, 108, 6-16.	0.8	92
27	Practice Recommendations for Risk-Adapted Head and Neck Cancer Radiation Therapy During the COVID-19 Pandemic: An ASTRO-ESTRO Consensus Statement. International Journal of Radiation Oncology Biology Physics, 2020, 107, 618-627.	0.8	156
28	Matrix density drives 3D organotypic lymphatic vessel activation in a microfluidic model of the breast tumor microenvironment. Lab on A Chip, 2020, 20, 1586-1600.	6.0	40
29	Opioid use in patients undergoing treatment for oral cavity cancer. Journal of Pain Management (discontinued), 2020, 13, 167-173.	0.7	1
30	Randomized phase II/III confirmatory treatment selection design with a change of survival end points: Statistical design of Radiation Therapy Oncology Group 1216. Head and Neck, 2019, 41, 37-45.	2.0	10
31	Human organotypic lymphatic vessel model elucidates microenvironment-dependent signaling and barrier function. Biomaterials, 2019, 214, 119225.	11.4	61
32	Lessons Learned From Hurricane Maria in Puerto Rico: Practical Measures to Mitigate the Impact of a Catastrophic Natural Disaster on Radiation Oncology Patients. Practical Radiation Oncology, 2019, 9, 305-321.	2.1	51
33	Open the Gates for Treatment De-Intensification in Head and Neck Cancer. Journal of Clinical Oncology, 2019, 37, 1854-1855.	1.6	1
34	Auriculotemporal Nerve Involvement in Parotid Bed Malignancy. Annals of Otology, Rhinology and Laryngology, 2019, 128, 647-653.	1,1	4
35	Reducing radiotherapy target volume expansion for patients with HPV-associated oropharyngeal cancer. Oral Oncology, 2019, 92, 52-56.	1.5	20
36	Personalized Treatment for Lacrimal Sac Adenoid Cystic Carcinoma: Case Report and Literature Review. Practical Radiation Oncology, 2019, 9, 136-141.	2.1	2

#	Article	IF	CITATIONS
37	A Multi-Institutional Experience of MR-Guided Liver Stereotactic Body Radiation Therapy. Advances in Radiation Oncology, 2019, 4, 142-149.	1.2	121
38	Nationwide Survey of Patients' Perspectives Regarding Their Radiation and Multidisciplinary Cancer Treatment Experiences. Journal of Oncology Practice, 2019, 15, e1010-e1017.	2.5	14
39	Radiotherapy plus cetuximab or cisplatin in human papillomavirus-positive oropharyngeal cancer (NRG) Tj ETQq1	1 0.78431 13.7	.4 rgBT /Ove
40	When Disaster Strikes: Mitigating the Adverse Impact on Head and Neck Cancer Patients. International Journal of Radiation Oncology Biology Physics, 2018, 100, 838-840.	0.8	5
41	Combining precision radiotherapy with molecular targeting and immunomodulatory agents: a guideline by the American Society for Radiation Oncology. Lancet Oncology, The, 2018, 19, e240-e251.	10.7	108
42	Impact of HPV Status on the Prognostic Potential of the AJCC Staging System for Larynx Cancer. Otolaryngology - Head and Neck Surgery, 2018, 159, 456-465.	1.9	8
43	Survival Outcomes for Patients With T3N0M0 Squamous Cell Carcinoma of the Glottic Larynx—Reply. JAMA Otolaryngology - Head and Neck Surgery, 2018, 144, 543.	2.2	0
44	A New Era of Image Guidance with Magnetic Resonance-guided Radiation Therapy for Abdominal and Thoracic Malignancies. Cureus, 2018, 10, e2422.	0.5	50
45	Is HPVâ€Associated Oropharyngeal Cancer Becoming More Common in Older Patients?. Laryngoscope Investigative Otolaryngology, 2018, 3, 446-449.	1.5	3
46	Results From 10 Years of a Free Oral Cancer Screening Clinic at a Major Academic Health Center. International Journal of Radiation Oncology Biology Physics, 2018, 102, 146-148.	0.8	0
47	Tumor-Specific Inhibition of <i>In Situ</i> Vaccination by Distant Untreated Tumor Sites. Cancer Immunology Research, 2018, 6, 825-834.	3.4	61
48	MERTK Mediates Intrinsic and Adaptive Resistance to AXL-targeting Agents. Molecular Cancer Therapeutics, 2018, 17, 2297-2308.	4.1	36
49	Enhanced Radiosensitivity in Solid Tumors using a Tumor-selective Alkyl Phospholipid Ether Analog. Molecular Cancer Therapeutics, 2018, 17, 2320-2328.	4.1	4
50	Obituary and Tribute to John "Jack―Francis Fowler, PhD, DSc (1925-2016). International Journal of Radiation Oncology Biology Physics, 2017, 97, 886-888.	0.8	1
51	Identification of stable housekeeping genes in response to ionizing radiation in cancer research. Scientific Reports, 2017, 7, 43763.	3.3	31
52	Small cell carcinoma of the head and neck: An analysis of the National Cancer Database. Oral Oncology, 2017, 69, 92-98.	1.5	59
53	Chondroradionecrosis of the larynx: 24â€year University of Wisconsin experience. Head and Neck, 2017, 39, 1189-1194.	2.0	14
54	Dosimetric Comparison of Real-Time MRI-Guided Tri-Cobalt-60 Versus Linear Accelerator-Based Stereotactic Body Radiation Therapy Lung Cancer Plans. Technology in Cancer Research and Treatment, 2017, 16, 366-372.	1.9	10

#	Article	IF	CITATIONS
55	Lymph Node Yield in Therapeutic Neck Dissection: Impact of Dissection Levels and Prior Radiotherapy. Annals of Otology, Rhinology and Laryngology, 2017, 126, 762-767.	1.1	6
56	Survival Outcomes for Patients With T3N0M0 Squamous Cell Carcinoma of the Glottic Larynx. JAMA Otolaryngology - Head and Neck Surgery, 2017, 143, 1126.	2.2	23
57	Transcriptional-mediated effects of radiation on the expression of immune susceptibility markers in melanoma. Radiotherapy and Oncology, 2017, 124, 418-426.	0.6	18
58	Clinical outcomes for patients presenting with N3 head and neck squamous cell carcinoma: Analysis of the National Cancer Database. Head and Neck, 2017, 39, 2159-2170.	2.0	13
59	Prognostic implications of human papillomavirus status for patients with non-oropharyngeal head and neck squamous cell carcinomas. Journal of Cancer Research and Clinical Oncology, 2017, 143, 2341-2350.	2.5	30
60	Why So Challenging to Personalize Radiation Dose?. International Journal of Radiation Oncology Biology Physics, 2017, 98, 1012-1013.	0.8	2
61	Radiosensitization of Adenoid Cystic Carcinoma with MDM2 Inhibition. Clinical Cancer Research, 2017, 23, 6044-6053.	7.0	27
62	Outcomes for patients with head and neck squamous cell carcinoma presenting with N3 nodal disease. Cancers of the Head & Neck, 2017, 2, .	6.2	8
63	HPV impacts survival of stage IVC non-oropharyngeal HNSCC cancer patients. Otorhinolaryngology-head and Neck Surgery, 2017, 2, .	0.1	8
64	Randomized Phase II Study of Duligotuzumab (MEHD7945A) vs. Cetuximab in Squamous Cell Carcinoma of the Head and Neck (MEHGAN Study). Frontiers in Oncology, 2016, 6, 232.	2.8	82
65	Assessing p16 Status of Oropharyngeal Squamous Cell Carcinoma by Combined Assessment of the Number of Cells Stained and the Confluence of p16 Staining. American Journal of Surgical Pathology, 2016, 40, 1261-1269.	3.7	23
66	Selective omission of level V nodal coverage for patients with oropharyngeal cancer: Clinical validation of intensityâ€modulated radiotherapy experience and dosimetric significance. Head and Neck, 2016, 38, 499-505.	2.0	9
67	Simulation study of high-dose-rate brachytherapy for early glottic cancer. Brachytherapy, 2016, 15, 94-101.	0.5	Ο
68	<i>In Situ</i> Tumor Vaccination by Combining Local Radiation and Tumor-Specific Antibody or Immunocytokine Treatments. Cancer Research, 2016, 76, 3929-3941.	0.9	120
69	Insulin growth factor 1 like receptor (IGF-1R). BMC Cancer, 2016, 16, 773.	2.6	12
70	Association of human papillomavirus and p16 status with mucositis and dysphagia for head and neck cancer patients treated with radiotherapy with or without cetuximab: Assessment from a phase 3 registration trial. European Journal of Cancer, 2016, 64, 1-11.	2.8	26
71	Establishing quality indicators for neck dissection: Correlating the number of lymph nodes with oncologic outcomes (NRG Oncology RTOG 9501 and RTOG 0234). Cancer, 2016, 122, 3464-3471.	4.1	70
72	Radiation Dose Escalation in Esophageal Cancer Revisited: A Contemporary Analysis of the National Cancer Data Base, 2004 to 2012. International Journal of Radiation Oncology Biology Physics, 2016, 96, 985-993.	0.8	67

#	Article	IF	CITATIONS
73	Correlation Between the Severity of Cetuximab-Induced Skin Rash and Clinical Outcome for Head and Neck Cancer Patients: TheÂRTOG Experience. International Journal of Radiation Oncology Biology Physics, 2016, 95, 1346-1354.	0.8	28
74	Gadoxetate for direct tumor therapy and tracking with real-time MRI-guided stereotactic body radiation therapy of the liver. Radiotherapy and Oncology, 2016, 118, 416-418.	0.6	59
75	Increased tumor response to neoadjuvant therapy among rectal cancer patients taking angiotensinâ€converting enzyme inhibitors or angiotensin receptor blockers. Cancer, 2016, 122, 2487-2495.	4.1	39
76	Pan-HER Inhibitor Augments Radiation Response in Human Lung and Head and Neck Cancer Models. Clinical Cancer Research, 2016, 22, 633-643.	7.0	20
77	Association of Human Papillomavirus and p16 Status With Outcomes in the IMCL-9815 Phase III Registration Trial for Patients With Locoregionally Advanced Oropharyngeal Squamous Cell Carcinoma of the Head and Neck Treated With Radiotherapy With or Without Cetuximab. Journal of Clinical Oncology. 2016. 34. 1300-1308.	1.6	190
78	Oropharyngeal Cancer. , 2016, , 597-628.e6.		1
79	Molecular Targeting of Growth Factor Receptor Signaling in Radiation Oncology. Recent Results in Cancer Research, 2016, 198, 45-87.	1.8	4
80	Molecular Targeted Therapies in Head and Neck Cancer. , 2016, , 349-372.		0
81	Xenograft assessment of predictive biomarkers for standard head and neck cancer therapies. Cancer Medicine, 2015, 4, 699-712.	2.8	18
82	Phase 1 Trial of Bevacizumab With Concurrent Chemoradiation Therapy for Squamous Cell Carcinoma of the Head and Neck With Exploratory Functional Imaging of Tumor Hypoxia, Proliferation, and Perfusion. International Journal of Radiation Oncology Biology Physics, 2015, 91, 942-951.	0.8	44
83	Incidental Parotid Neoplasms. Otolaryngology - Head and Neck Surgery, 2015, 153, 566-568.	1.9	7
84	Antitumor Effects of MEHD7945A, a Dual-Specific Antibody against EGFR and HER3, in Combination with Radiation in Lung and Head and Neck Cancers. Molecular Cancer Therapeutics, 2015, 14, 2049-2059.	4.1	28
85	Therapeutic combination of radiolabeled CLR1404 with external beam radiation in head and neck cancer model systems. Radiotherapy and Oncology, 2015, 116, 504-509.	0.6	18
86	Quantitative evaluation of image segmentation incorporating medical consideration functions. Medical Physics, 2015, 42, 3013-3023.	3.0	24
87	Patient and tumor characteristics predictive of primary parotid gland malignancy: A 20-year experience at the University of Wisconsin. American Journal of Otolaryngology - Head and Neck Medicine and Surgery, 2015, 36, 429-434.	1.3	5
88	Small Molecule Inhibition of MDM2–p53 Interaction Augments Radiation Response in Human Tumors. Molecular Cancer Therapeutics, 2015, 14, 1994-2003.	4.1	35
89	Impact of Node Negative Target Volume Delineation on Contralateral Parotid Gland Dose Sparing Using IMRT in Head and Neck Cancer. Technology in Cancer Research and Treatment, 2015, 14, 315-319.	1.9	0
90	The prognostic value of HPV in head and neck cancer patients undergoing postoperative chemoradiotherapy. Annals of Translational Medicine, 2015, 3, S14.	1.7	8

#	Article	IF	CITATIONS
91	p16 Protein Expression and Human Papillomavirus Status As Prognostic Biomarkers of Nonoropharyngeal Head and Neck Squamous Cell Carcinoma. Journal of Clinical Oncology, 2014, 32, 3930-3938.	1.6	313
92	Interaction of Radiation Therapy With Molecular Targeted Agents. Journal of Clinical Oncology, 2014, 32, 2886-2893.	1.6	77
93	Postoperative Chemoradiotherapy and Cetuximab for High-Risk Squamous Cell Carcinoma of the Head and Neck: Radiation Therapy Oncology Group RTOG-0234. Journal of Clinical Oncology, 2014, 32, 2486-2495.	1.6	180
94	Is radiation dose reduction the right answer for HPV-positive head and neck cancer?. Oral Oncology, 2014, 50, 560-564.	1.5	37
95	Increased local failure risk with prolonged radiation treatment time in head and neck cancer treated with concurrent chemotherapy. Head and Neck, 2014, 36, 1120-1125.	2.0	42
96	Impact of p16 status on the results of the phase III cetuximab (cet)/radiotherapy (RT) Journal of Clinical Oncology, 2014, 32, 6001-6001.	1.6	25
97	Dual Targeting of EGFR and HER3 with MEHD7945A Overcomes Acquired Resistance to EGFR Inhibitors and Radiation. Cancer Research, 2013, 73, 824-833.	0.9	165
98	Risk of Cerebrovascular Events in Elderly Patients After Radiation Therapy Versus Surgery for Early-Stage Glottic Cancer. International Journal of Radiation Oncology Biology Physics, 2013, 87, 290-296.	0.8	32
99	Sym004, a Novel Anti-ECFR Antibody Mixture, Augments Radiation Response in Human Lung and Head and Neck Cancers. Molecular Cancer Therapeutics, 2013, 12, 2772-2781.	4.1	13
100	Development and Characterization of HPV-Positive and HPV-Negative Head and Neck Squamous Cell Carcinoma Tumorgrafts. Clinical Cancer Research, 2013, 19, 855-864.	7.0	85
101	Acute Hematologic and Mucosal Toxicities in Head and Neck Cancer Patients Undergoing Chemoradiotherapy: A Comparison of 3D-CRT, IMRT, and Helical Tomotherapy. Technology in Cancer Research and Treatment, 2013, 12, 383-389.	1.9	12
102	Enhanced Radiation Sensitivity in HPV-Positive Head and Neck Cancer. Cancer Research, 2013, 73, 4791-4800.	0.9	317
103	The Relative Expression of Mig6 and EGFR Is Associated with Resistance to EGFR Kinase Inhibitors. PLoS ONE, 2013, 8, e68966.	2.5	31
104	Correlation of PET images of metabolism, proliferation and hypoxia to characterize tumor phenotype in patients with cancer of the oropharynx. Radiotherapy and Oncology, 2012, 105, 36-40.	0.6	37
105	Heterogeneity in head and neck IMRT target design and clinical practice. Radiotherapy and Oncology, 2012, 103, 92-98.	0.6	130
106	Head and neck carcinoma in the United States. Cancer, 2012, 118, 5783-5792.	4.1	53
107	Oropharyngeal Cancer. , 2012, , 585-617.		0
108	Enhanced apoptosis and altered DNA repair underlie improved outcomes in HPVâ€positive head and neck cancer. FASEB Journal, 2012, 26, 537.2.	0.5	0

#	Article	IF	CITATIONS
109	Longitudinal oncology registry of head and neck carcinoma (LORHAN). Cancer, 2011, 117, 1679-1686.	4.1	41
110	p53 Modulates Acquired Resistance to EGFR Inhibitors and Radiation. Cancer Research, 2011, 71, 7071-7079.	0.9	105
111	Abstract 637: MEHD7945A, an EGFR/ErbB3 dual specific antibody, overcomes acquired resistance to EGFR inhibitors in head and neck and lung tumors. Cancer Research, 2011, 71, 637-637.	0.9	6
112	EGFR Signaling and Radiation. , 2011, , 201-226.		0
113	Comprehensive IMRT plus weekly cisplatin for advanced head and neck cancer: The University of Wisconsin experience. Head and Neck, 2010, 32, 599-606.	2.0	56
114	Multi-Institutional Trial of Accelerated Hypofractionated Intensity-Modulated Radiation Therapy for Early-Stage Oropharyngeal Cancer (RTOG 00-22). International Journal of Radiation Oncology Biology Physics, 2010, 76, 1333-1338.	0.8	336
115	Emphasizing Conformal Avoidance Versus Target Definition for IMRT Planning in Head-and-Neck Cancer. International Journal of Radiation Oncology Biology Physics, 2010, 77, 950-958.	0.8	78
116	Regulation of Heparin-Binding EGF-Like Growth Factor by miR-212 and Acquired Cetuximab-Resistance in Head and Neck Squamous Cell Carcinoma. PLoS ONE, 2010, 5, e12702.	2.5	128
117	Augmentation of Radiation Response by Motesanib, a Multikinase Inhibitor that Targets Vascular Endothelial Growth Factor Receptors. Clinical Cancer Research, 2010, 16, 3639-3647.	7.0	14
118	Understanding resistance to EGFR inhibitors—impact on future treatment strategies. Nature Reviews Clinical Oncology, 2010, 7, 493-507.	27.6	593
119	Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival. Lancet Oncology, The, 2010, 11, 21-28.	10.7	1,773
120	Radiotherapy and Chemotherapy. , 2010, , 82-94.		0
121	Robotics in head and neck cancer: future opportunities. Oncology, 2010, 24, 1015, 1020, 1022.	0.5	Ο
122	Establishment and Characterization of a Model of Acquired Resistance to Epidermal Growth Factor Receptor Targeting Agents in Human Cancer Cells. Clinical Cancer Research, 2009, 15, 1585-1592.	7.0	94
123	Epidermal Growth Factor Receptor cooperates with Src Family Kinases in acquired resistance to cetuximab. Cancer Biology and Therapy, 2009, 8, 696-703.	3.4	138
124	Molecular Target Approaches in Head and Neck Cancer: Epidermal Growth Factor Receptor and Beyond. Seminars in Radiation Oncology, 2009, 19, 63-68.	2.2	63
125	Hidradenomas and a Hidradenocarcinoma of the Scalp Managed Using Mohs Micrographic Surgery and a Multidisciplinary Approach. Dermatologic Surgery, 2009, 35, 273-281.	0.8	29
126	A Comprehensive Assessment by Tumor Site of Patient Setup Using Daily MVCT Imaging From More Than 3,800 Helical Tomotherapy Treatments. International Journal of Radiation Oncology Biology Physics, 2009, 73, 1260-1269.	0.8	90

#	Article	IF	CITATIONS
127	Hypopharynx. Medical Radiology, 2009, , 31-41.	0.1	Ο
128	Contributions of Targeted Agents. Medical Radiology, 2009, , 215-223.	0.1	0
129	Adjuvant Therapy for Patients with Oral Cavity Cancer. , 2009, , 121-134.		0
130	EGFR inhibitors for the treatment of squamous cell carcinoma of the head and neck. Current Oncology Reports, 2008, 10, 176-184.	4.0	8
131	Augmentation of Radiation Response by Panitumumab in Models of Upper Aerodigestive Tract Cancer. International Journal of Radiation Oncology Biology Physics, 2008, 72, 534-542.	0.8	41
132	Beware the Swing and a Miss: Baseball Precautions for Conformal Radiotherapy. International Journal of Radiation Oncology Biology Physics, 2008, 70, 657-659.	0.8	20
133	Radiation Oncology Advances: An Introduction. Cancer Treatment and Research, 2008, 139, 1-4.	0.5	5
134	Clinical Application of EGFR Inhibitors in Head and Neck Squamous Cell Cancer. Cancer Treatment and Research, 2008, , 132-149.	0.5	1
135	Quality of Life in Head and Neck Cancer Patients After Treatment With High-Dose Radiotherapy Alone or in Combination With Cetuximab. Journal of Clinical Oncology, 2007, 25, 2191-2197.	1.6	225
136	Biology of Interactions: Antiepidermal Growth Factor Receptor Agents. Journal of Clinical Oncology, 2007, 25, 4057-4065.	1.6	209
137	Insulin-like Growth Factor-I Receptor Signaling Blockade Combined with Radiation. Cancer Research, 2007, 67, 1155-1162.	0.9	98
138	Megavoltage Computed Tomography. American Journal of Clinical Oncology: Cancer Clinical Trials, 2007, 30, 617-623.	1.3	31
139	Parotidectomy: Ten-Year Review of 237 Cases at a Single Institution. Otolaryngology - Head and Neck Surgery, 2007, 136, 788-792.	1.9	123
140	Stepwise Progress in Epidermal Growth Factor Receptor/Radiation Studies for Head and Neck Cancer. International Journal of Radiation Oncology Biology Physics, 2007, 69, S25-S27.	0.8	4
141	Strategic Plans to Promote Head and Neck Cancer Translational Research Within the Radiation Therapy Oncology Group: A Report From the Translational Research Program. International Journal of Radiation Oncology Biology Physics, 2007, 69, S67-S78.	0.8	13
142	Are We Influencing Outcome in Oropharynx Cancer With Intensity-Modulated Radiotherapy? An Inter-Era Comparison. International Journal of Radiation Oncology Biology Physics, 2007, 69, 1032-1041.	0.8	63
143	Planned Postradiotherapy Neck Dissection: Rationale and Clinical Outcomes. Laryngoscope, 2007, 117, 121-128.	2.0	41
144	Exploitable mechanisms for combining drugs with radiation: concepts, achievements and future directions. Nature Clinical Practice Oncology, 2007, 4, 172-180.	4.3	129

#	Article	IF	CITATIONS
145	The Advancement of Epidermal Growth Factor Receptor Inhibitors in Cancer Therapy. , 2007, , 335-357.		0
146	Radiotherapy plus Cetuximab for Squamous-Cell Carcinoma of the Head and Neck. New England Journal of Medicine, 2006, 354, 567-578.	27.0	4,705
147	Augmentation of radiation response with the vascular targeting agent ZD6126. International Journal of Radiation Oncology Biology Physics, 2006, 64, 1458-1465.	0.8	32
148	Impact of conventional radiotherapy on health-related quality of life and critical functions of the head and neck. International Journal of Radiation Oncology Biology Physics, 2006, 65, 1051-1062.	0.8	75
149	Biologic Basis for Combining Drugs With Radiation. Seminars in Radiation Oncology, 2006, 16, 2-9.	2.2	167
150	Radiation Combined With EGFR Signal Inhibitors: Head and Neck Cancer Focus. Seminars in Radiation Oncology, 2006, 16, 38-44.	2.2	78
151	Radiation and New Molecular Agents, Part II: Targeting HDAC, HSP90, IGF-1R, PI3K, and Ras. Seminars in Radiation Oncology, 2006, 16, 59-64.	2.2	52
152	Enhancing the antitumor activity of ErbB blockade with histone deacetylase (HDAC) inhibition. International Journal of Cancer, 2006, 118, 1041-1050.	5.1	41
153	EGFR-Targeting Monoclonal Antibodies in Head and Neck Cancer. Current Cancer Drug Targets, 2006, 6, 691-710.	1.6	40
154	Clinical Implementation of Adaptive Helical Tomotherapy: A Unique Approach to Image-Guided Intensity Modulated Radiotherapy. Technology in Cancer Research and Treatment, 2006, 5, 465-479.	1.9	83
155	Anti-EGFR therapy update: clinical experience and adverse event insights. Oncology, 2006, 20, 3-4.	0.5	7
156	The impact of daily setup variations on head-and-neck intensity-modulated radiation therapy. International Journal of Radiation Oncology Biology Physics, 2005, 61, 779-788.	0.8	255
157	Modulation of radiation response by histone deacetylase inhibition. International Journal of Radiation Oncology Biology Physics, 2005, 62, 223-229.	0.8	231
158	Angiogenesis and radiation response modulation after vascular endothelial growth factor receptor-2 (VEGFR2) blockade. International Journal of Radiation Oncology Biology Physics, 2005, 62, 1477-1485.	0.8	73
159	Precautions in the Use of Intensity-Modulated Radiation Therapy. Technology in Cancer Research and Treatment, 2005, 4, 203-210.	1.9	18
160	Mechanisms of Enhanced Radiation Response following Epidermal Growth Factor Receptor Signaling Inhibition by Erlotinib (Tarceva). Cancer Research, 2005, 65, 3328-3335.	0.9	359
161	Intensity-Modulated Radiation Therapy in the Management of Head and Neck Cancer. , 2005, , 115-124.		1
162	Dual-Agent Molecular Targeting of the Epidermal Growth Factor Receptor (EGFR). Cancer Research, 2004, 64, 5355-5362.	0.9	369

#	Article	IF	CITATIONS
163	Searching for Reliable Epidermal Growth Factor Receptor Response Predictors. Clinical Cancer Research, 2004, 10, 428-432.	7.0	18
164	Combining EGFR inhibitors with radiation or chemotherapy: will preclinical studies predict clinical results?. International Journal of Radiation Oncology Biology Physics, 2004, 58, 976-983.	0.8	73
165	Chemoradiation for upper aerodigestive tract cancer: balancing evidence from clinical trials with individual patient recommendations. Current Problems in Cancer, 2004, 28, 7-40.	2.0	17
166	Acute radiation reactions in oral and pharyngeal mucosa: tolerable levels in altered fractionation schedules. Radiotherapy and Oncology, 2003, 69, 161-168.	0.6	121
167	Clinical promise tempered by reality in the delivery of combined chemoradiation for common solid tumors. Seminars in Radiation Oncology, 2003, 13, 3-12.	2.2	20
168	Promising New Approaches in the Treatment of Advanced Head and Neck Cancer. American Journal of Cancer, 2003, 2, 335-347.	0.4	1
169	Helical Tomotherapy: An Innovative Technology and Approach to Radiation Therapy. Technology in Cancer Research and Treatment, 2002, 1, 311-316.	1.9	149
170	Epidermal growth factor receptor modulation of radiation response: Preclinical and clinical development. Seminars in Radiation Oncology, 2002, 12, 21-26.	2.2	49
171	Modulation of radiation response and tumor-induced angiogenesis after epidermal growth factor receptor inhibition by ZD1839 (Iressa). Cancer Research, 2002, 62, 4300-6.	0.9	196
172	Molecular inhibition of angiogenesis and metastatic potential in human squamous cell carcinomas after epidermal growth factor receptor blockade. Molecular Cancer Therapeutics, 2002, 1, 507-14.	4.1	98
173	IMC-C225, an anti-epidermal growth factor receptor monoclonal antibody, for treatment of head and neck cancer. Expert Opinion on Biological Therapy, 2001, 1, 719-732.	3.1	98
174	Multiple daily fractionation radiotherapy schedules in lung cancer. Current Oncology Reports, 2001, 3, 179-184.	4.0	4
175	Head and neck cancer as a clinical model for molecular targeting of therapy: combining EGFR blockade with radiation. International Journal of Radiation Oncology Biology Physics, 2001, 49, 427-433.	0.8	201
176	Radiation response modification following molecular inhibition of epidermal growth factor receptor signaling. Seminars in Radiation Oncology, 2001, 11, 281-289.	2.2	95
177	Epidermal Growth Factor Receptor Inhibition in Cancer Therapy: Biology, Rationale and Preliminary Clinical Results. Investigational New Drugs, 1999, 17, 259-269.	2.6	222
178	Planned postradiotherapy neck dissection in patients with advanced head and neck cancer. Head and Neck, 1998, 20, 132-137.	2.0	101
179	Improving dose homogeneity in routine head and neck radiotherapy with custom 3-D compensation. Radiotherapy and Oncology, 1998, 49, 67-71.	0.6	16
180	Altered Fractionation Strategies in Radiation Oncology for the Head and Neck Cancer Patient. Oral and Maxillofacial Surgery Clinics of North America, 1997, 9, 425-432.	1.0	0

#	Article	IF	CITATIONS
181	Advances in radiation therapy for head and neck cancer. Current Opinion in Oncology, 1995, 7, 248-254.	2.4	12
182	Slowing proliferation in head and neck tumors: In vitro growth inhibitory effects of the polyamine analog BE-4-4-4-4 in human squamous cell carcinomas. International Journal of Radiation Oncology Biology Physics, 1995, 32, 687-694.	0.8	6
183	Oral tongue cancer in young adults less than 40 years of age: Rationale for aggressive therapy. Head and Neck, 1994, 16, 107-111.	2.0	181
184	Combining polyamine depletion with radiation therapy for rapidly dividing head and neck tumors: Strategies for improved locoregional control. International Journal of Radiation Oncology Biology Physics, 1994, 28, 891-898.	0.8	13
185	Idealized versus realized overall treatment times. International Journal of Radiation Oncology Biology Physics, 1994, 29, 209-211.	0.8	17
186	Evaluation and quality control of a commercial 3-D dose compensator system. Medical Dosimetry, 1994, 19, 179-185.	0.9	2
187	Dose intensification in curative head and neck cancer radiotherapy—Linear quadratic analysis and preliminary assessment of clinical results. International Journal of Radiation Oncology Biology Physics, 1993, 27, 363-369.	0.8	26
188	Pterygium treated with excision and postoperative beta irradiation. International Journal of Radiation Oncology Biology Physics, 1992, 23, 533-537.	0.8	60
189	Adding dose escalation to accelerated hyperfractionation for head and neck cancer: 76 Gy in 5 weeks. Seminars in Radiation Oncology, 1992, 2, 58-61.	2.2	24
190	Intubation granuloma of the larynx: Successful eradication with low-dose radiotherapy. Head and Neck, 1991, 13, 230-233.	2.0	20
191	The role of radiotherapy in the treatment of malignant sweat gland neoplasms. Cancer, 1990, 65, 1737-1740.	4.1	84